31
Participants
Start Date
April 26, 2018
Primary Completion Date
December 4, 2018
Study Completion Date
July 27, 2023
Tamoxifen
20 mg orally
Vorinostat
400 mg orally
Antiretroviral drugs
Participants will receive antiretroviral drugs provided by their own doctors. Antiretroviral drugs will not be provided by the study.
Penn Therapeutics, CRS, Philadelphia
Whitman-Walker Health CRS, Washington D.C.
Greensboro CRS, Greensboro
Chapel Hill CRS, Chapel Hill
Alabama CRS, Birmingham
Cincinnati Clinical Research Site, Cincinnati
Northwestern University CRS, Chicago
University of Colorado Hospital CRS, Aurora
UCLA CARE Center CRS, Los Angeles
Harbor-UCLA CRS, Torrance
Ucsf Hiv/Aids Crs, San Francisco
The Ponce de Leon Center CRS, Atlanta
Massachusetts General Hospital CRS (MGH CRS), Boston
New Jersey Medical School Clinical Research Center CRS, Newark
Puerto Rico AIDS Clinical Trials Unit CRS, San Juan
National Institute of Allergy and Infectious Diseases (NIAID)
NIH